Processa Acquires Vidya with $200 Million Financing

Company Processa Pharmaceuticals / Vidya Discovery Event Type Acquisition and Private Placement Financing Modality Covalent, CNS-penetrant BTK inhibitor Asset VT-7208 Target BTK (Bruton’s tyrosine kinase) Disease Area Food allergy, chronic spontaneous urticaria, and relapsing multiple sclerosis Summary Processa Pharmaceuticals acquired Vidya Discovery stock-for-stock and announced…